How does 0JXI's PB Ratio compare to its peers?

0JXI is expensive based on its Price-To-Book Ratio (9.8x) compared to the peer average (4.7x).

How does 0JXI's PB Ratio compare vs other companies in the GB Biotechs Industry?

0JXI is expensive based on its Price-To-Book Ratio (9.8x) compared to the UK Biotechs industry average (2.9x).

What is 0JXI's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 0JXI's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of 0JXI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

0JXI ($343.85) is trading below our estimate of [[fair value]] ($1943.87)

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is less than 20% higher than the current share price.

Madrigal Pharmaceuticals (LSE:0JXI) - Stock Price, News & Analysis

0JXI Stock Overview

A clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. More details

0JXI fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 82.3% below our estimate of its fair value

Earnings are forecast to grow 73.08% per year

Risk Analysis

Highly volatile share price over the past 3 months compared to the UK market

Significant insider selling over the past 3 months

Shareholders have been diluted in the past year

Madrigal Pharmaceuticals, Inc. Competitors

Genus

LSE:GNS

UK£1.1b

Avacta Group

AIM:AVCT

UK£179.3m

Oxford Biomedica

LSE:OXB

UK£442.5m

Krystal Biotech

NasdaqGS:KRYS

US$5.5b

Price History & Performance

Summary of all time highs, changes and price drops for Madrigal Pharmaceuticals
Historical stock prices
Current Share Price	US$343.85
52 Week High	US$363.57
52 Week Low	US$168.17
Beta	-0.47
11 Month Change	62.41%
3 Month Change	34.38%
1 Year Change	76.01%
33 Year Change	284.02%
5 Year Change	n/a
Change since IPO	182.31%

Recent updates

Shareholder Returns

	0JXI	GB Biotechs	GB Market
7D	24.3%	0.3%	2.2%
1Y	76.0%	-18.3%	8.0%

Return vs Industry: 0JXI exceeded the UK Biotechs industry which returned -18.3% over the past year.

Return vs Market: 0JXI exceeded the UK Market which returned 8% over the past year.

Price Volatility

Is 0JXI's price volatile compared to industry and market?
0JXI volatility
0JXI Average Weekly Movement	11.0%
Biotechs Industry Average Movement	9.7%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: 0JXI's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0JXI's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

Founded	Employees	CEO	Website
n/a	376	Bill Sibold	www.madrigalpharma.com

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal Pharmaceuticals, Inc. Fundamentals Summary

How do Madrigal Pharmaceuticals's earnings and revenue compare to its market cap?
0JXI fundamental statistics
Market cap	US$7.58b
Earnings (TTM)	-US$518.67m
Revenue (TTM)	US$76.81m

98.7x

P/S Ratio

-14.6x

P/E Ratio

Is 0JXI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0JXI income statement (TTM)
Revenue	US$76.81m
Cost of Revenue	US$2.79m
Gross Profit	US$74.03m
Other Expenses	US$592.70m
Earnings	-US$518.67m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-23.78
Gross Margin	96.37%
Net Profit Margin	-675.24%
Debt/Equity Ratio	15.1%

How did 0JXI perform over the long term?

See historical performance and comparison

0JXI Stock Overview

Rewards

Risk Analysis

Madrigal Pharmaceuticals, Inc. Competitors

LSE:GNS

UK£1.1b

AIM:AVCT

UK£179.3m

LSE:OXB

UK£442.5m

NasdaqGS:KRYS

US$5.5b

Price History & Performance

Recent News & Updates

Madrigal Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Forecast to breakeven in 2026

Madrigal Pharmaceuticals, Inc. Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development

CEO, President & Director recently sold US$1.6m worth of stock

Madrigal Pharmaceuticals, Inc. Appoints Shannon Kelley as General Counsel

Madrigal Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Recent updates

Madrigal Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Forecast to breakeven in 2026

Madrigal Pharmaceuticals, Inc. Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development

CEO, President & Director recently sold US$1.6m worth of stock

Madrigal Pharmaceuticals, Inc. Appoints Shannon Kelley as General Counsel

Madrigal Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Madrigal Pharmaceuticals, Inc. Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra (resmetirom) Presented at the EASL Congress

No longer forecast to breakeven

Madrigal Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Madrigal Pharmaceuticals, Inc., Annual General Meeting, Jun 25, 2024

Madrigal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 07, 2024

Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

Madrigal Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $599.999764 million.

Madrigal Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $599.999764 million.

Madrigal Pharmaceuticals, Inc. Announces FDA Approval of Rezdiffra™ (Resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (Nash) with Moderate to Advanced Liver Fibrosis

Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis

Forecast breakeven date moved forward to 2025

Madrigal Pharmaceuticals, Inc. Announces Management Changes

Madrigal Pharmaceuticals, Inc. Appoints CFO Changes

Forecast breakeven date pushed back to 2026

New major risk - Financial position

Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

New major risk - Share price stability

Madrigal Pharmaceuticals, Inc. Announces Additions to its Leadership Team

Madrigal Pharmaceuticals, Inc. Appoints Ronald Filippo as Chief Information Officer

Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer

New major risk - Financial position

Madrigal Pharmaceuticals, Inc. Announces the Resignation of Remy Sukhija as Chief Commercial Officer

Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of Nash with Liver

Madrigal Pharmaceuticals, Inc. Announces Chief Executive Officer Changes

Madrigal Pharmaceuticals, Inc. Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

Madrigal Pharmaceuticals, Inc. Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of Nash with Liver Fibrosis

Forecast to breakeven in 2025

Madrigal Pharmaceuticals, Inc. announced that it has received $90 million in funding

Madrigal Pharmaceuticals, Inc. Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis

Insufficient new directors

Insufficient new directors

Insufficient new directors

Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis

Insufficient new directors

Madrigal Pharmaceuticals, Inc. Presents Late-Breaking Phase 3 NASH Data and Multiple Oral Abstracts at EASL’s International Liver Congress™

Insufficient new directors

Madrigal Pharmaceuticals, Inc., Annual General Meeting, Jun 15, 2022

Insufficient new directors

Madrigal Pharmaceuticals Provides Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial Results

Insufficient new directors

Madrigal Pharmaceuticals, Inc. Announces Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular Health

Madrigal Pharmaceuticals to Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom

Insufficient new directors

Insufficient new directors

Madrigal Pharmaceuticals, Inc. Provides Update on Timeline for Topline Results from the Phase 3 MAESTRO-NAFLD-1 Clinical Trial of Resmetirom

Insufficient new directors

Insufficient new directors

Madrigal Pharmaceuticals, Inc. Offers Patients Resmetirom in Open Label Active Treatment Extension of the Phase 3 MAESTRO-NAFLD-1 Clinical Study

Madrigal Pharmaceuticals Completes Enrollment of the 52 Week Liver Biopsy Patient Population in the Phase 3 MAESTRO-NASH Study of Resmetirom

Madrigal Pharmaceuticals Announces Presentation of Positive Clinical Data of Resmetirom from Open-Label Portion of Ongoing Phase 3 Clinical Trial Maestro-Nafld-1

Shareholder Returns

Price Volatility

About the Company